Denosumab reduces the incidence of new vertebral fractures in men with prostate cancer

Current Osteoporosis Reports

Volumn 8, Issue 1, 2010, Pages 1-3

  Silver, David S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; GONADORELIN AGONIST; PLACEBO;

AGED; ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; INFECTION; JAW OSTEONECROSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOTE; ORCHIECTOMY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE;

EID: 77449140658     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-010-0001-8     Document Type: Note

References (6)

1. Smith MR, McGovern FJ, Zietman AL, et al.: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001, 345:948-955.
2. Michaelson MD, Kaufman DS, Lee H, et al.: Randomized controlled trial of annual zoledronic acid to prevent gonadotropinreleasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007, 25:1038-1042.
3. Smith MR, Eastham J, Gleason DM, et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008-2012.
4. Greenspan SL, Nelson JB, Trump DL, Resnick NM: Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007, 146:416-424.
5. Smith MR, Fallon MA, Lee H, Finkelstein HS: Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004, 89:3841-3846.
6. Fizazi K, Lipton A, Mariette X, et al.: Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, and other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009, 27:1564-1571.